Equitec Proprietary Markets’s Blueprint Medicines BPMC Stock Holding History

Equitec Proprietary Markets’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-92,500	Closed	-$11.9M	–	79
2025 Q2	$11.9M	Buy	+92,500	New	+$9.61M	11.2%	4

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Equitec Proprietary Markets's BPMC Position: Q3 2025 in Review

Equitec Proprietary Markets sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 92,500 shares — an estimated $11.9M sold.

Equitec Proprietary Markets first reported a position in BPMC in Q2 2025 and held it in 1 quarter. The position peaked at $11.9M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Equitec Proprietary Markets reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Equitec Proprietary Markets sold 92,500 Blueprint Medicines shares in Q3 2025, an estimated $11.9M.
Equitec Proprietary Markets first reported a position in Blueprint Medicines in Q2 2025 and held it in 1 quarter.
Equitec Proprietary Markets's Blueprint Medicines position peaked at $11.9M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Equitec Proprietary Markets's 13F filing for Q3 2025, filed 26 Nov 2025.